{
    "root": "347c92a4-d204-911e-e063-6294a90a169a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lisinopril",
    "value": "20250506",
    "ingredients": [
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "LISINOPRIL",
            "code": "E7199S1YWR"
        }
    ],
    "indications": "lisinopril tablet usp angiotensin converting enzyme ( ace ) inhibitor indicated : treatment hypertension adults pediatric patients 6 years age older ( 1.1 ) adjunct therapy heart failure ( 1.2 ) treatment acute myocardial infarction ( 1.3 )",
    "contraindications": "hypertension : initial adult dose 10 mg daily . titrate 40 mg daily based blood pressure response . initiate patients diuretics 5 mg daily ( 2.1 ) pediatric patients glomerular filtration rate > 30 ml/min/1.73m 2 : initial dose patients 6 years age older 0.07 mg per kg ( 5 mg total ) daily ( 2.1 ) heart failure : initiate 5 mg daily . increase dose tolerated 40 mg daily ( 2.2 ) acute myocardial infarction ( myocardial infarction ) : give 5 mg within 24 hours myocardial infarction . followed 5 mg 24 hours , 10 mg daily ( 2.3 ) renal impairment : patients creatinine clearance > 10 ml/min < 30 ml/min , halve usual initial dose . patients creatinine clearance < 10 ml/min hemodialysis , recommended initial dose 2.5 mg ( 2.4 )",
    "warningsAndPrecautions": "lisinopril tablet usp available uncoated biconvex tablets 10 mg , pink , round , score , imprint : lupin/10 ndc : 70518-1152-00 ndc : 70518-1152-01 ndc : 70518-1152-02 ndc : 70518-1152-03 ndc : 70518-1152-04 packaging : 30 1 blister pack packaging : 28 1 blister pack packaging : 90 1 bottle plastic packaging : 30 1 bottle plastic packaging : 30 1 bottle plastic store controlled room temperature , 20° 25°c ( 68° 77°f ) [ usp ] . protect moisture , freezing excessive heat . dispense tight container . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "angioedema history hereditary idiopathic angioedema ( 4 ) hypersensitivity ( 4 ) co-administration aliskiren lisinopril patients diabetes ( 4 , 7.4 )",
    "indications_original": "Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 )",
    "contraindications_original": "Hypertension: Initial adult dose is 10 mg once daily. Titrate up to 40 mg daily based on blood pressure response. Initiate patients on diuretics at 5 mg once daily ( 2.1 ) Pediatric patients with glomerular filtration rate > 30 mL/min/1.73m 2 : Initial dose in patients 6 years of age and older is 0.07 mg per kg (up to 5 mg total) once daily ( 2.1 ) Heart Failure: Initiate with 5 mg once daily. Increase dose as tolerated to 40 mg daily ( 2.2 ) Acute Myocardial Infarction (MI): Give 5 mg within 24 hours of MI. Followed by 5 mg after 24 hours, then 10 mg once daily ( 2.3) Renal Impairment: For patients with creatinine clearance > 10 mL/min and < 30 mL/min, halve usual initial dose. For patients with creatinine clearance < 10 mL/min or on hemodialysis, the recommended initial dose is 2.5 mg ( 2.4 )",
    "warningsAndPrecautions_original": "Lisinopril tablet USP is available as uncoated biconvex tablets in\n                  10 mg, pink, round, no score, imprint: LUPIN/10\n                  \n                  NDC: 70518-1152-00\n                  NDC: 70518-1152-01\n                  NDC: 70518-1152-02\n                  NDC: 70518-1152-03\n                  NDC: 70518-1152-04\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 28 in 1 BLISTER PACK\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC \n                  \n                  \n                  \n                  \n                  Store at controlled room temperature, 20° to 25°C (68° to 77°F) [see USP]. Protect from moisture, freezing and excessive heat. Dispense in a tight container.\n                  \n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Angioedema or a history of hereditary or idiopathic angioedema ( 4 ) Hypersensitivity ( 4 ) Co-administration of aliskiren with lisinopril in patients with diabetes ( 4 , 7.4 )"
}